Aurgalys Team
Selected Customers
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]

June 9th, 2015: Aurgalys releases new analyst reports on Onxeo [Euronext:ONXEO]

juin 09, 2015

Paris-Evry, France, June 9th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued new analyst report on Onxeo.

« Onxeo released the final results of Validive’s Phase II clinical trial, which confirmed the preliminary findings published last October. Taken daily over the course of the chemoradiotherapy treatment (8 weeks), Validive (clonidine Lauriad) was able to reduce the occurrence of Severe Oral Mucositis, while reducing chemoradiotherapy-related adverse events (nausea, dysphagia). This proof of concept establishes the basis of the Phase III study, expected to start at the end of 2015 […] »

You can download our report (in English) at the following link:

Comments are closed.